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Although class A G protein−coupled receptors (GPCRs) can func-
tion as monomers, many of them form dimers and oligomers, but
the mechanisms and functional relevance of such oligomerization
is ill understood. Here, we investigate this problem for the CXC
chemokine receptor 4 (CXCR4), a GPCR that regulates immune and
hematopoietic cell trafficking, and a major drug target in cancer
therapy. We combine single-molecule microscopy and fluores-
cence fluctuation spectroscopy to investigate CXCR4 membrane
organization in living cells at densities ranging from a few mole-
cules to hundreds of molecules per square micrometer of the
plasma membrane. We observe that CXCR4 forms dynamic, tran-
sient homodimers, and that the monomer−dimer equilibrium is
governed by receptor density. CXCR4 inverse agonists that bind
to the receptor minor pocket inhibit CXCR4 constitutive activity
and abolish receptor dimerization. A mutation in the minor bind-
ing pocket reduced the dimer-disrupting ability of these ligands. In
addition, mutating critical residues in the sixth transmembrane
helix of CXCR4 markedly diminished both basal activity and dimer-
ization, supporting the notion that CXCR4 basal activity is required
for dimer formation. Together, these results link CXCR4 dimeriza-
tion to its density and to its activity. They further suggest that
inverse agonists binding to the minor pocket suppress both dimer-
ization and constitutive activity and may represent a specific strat-
egy to target CXCR4.
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Gprotein−coupled receptors (GPCRs) constitute the largestclass of cell surface receptors and are the main targets of
clinically approved drugs (1). While GPCRs have classically been
thought to exist and function as simple monomers, substantial
data show that many of them may form dimers and higher-order
oligomers, which might be relevant for their function (2). In
particular, it is now well-appreciated that class C GPCRs form
obligatory dimers (3) and that intermolecular rearrangements of
such dimers play a key role for receptor activation (4, 5). Even
though members of the much larger family of class A GPCRs
have been shown to transduce signals as monomeric entities (6),
emerging evidence demonstrates that they can form oligomers
both in vitro and in vivo (7, 8). Several recent studies using ad-
vanced fluorescence microscopy methods suggested a dynamic
nature of dimerization for a number of class A GPCRs (9–12).
Thus, the stability, dynamics and functional relevance of indi-
vidual class A GPCR dimers remains debatable.
The CXC chemokine receptor 4 (CXCR4) is a prime example
of a class A GPCR where the quaternary organization may be
functionally and pharmacologically important. While CXCR4
regulates physiological processes mainly associated with cell
migration and development, dysregulation of CXCR4 expression
and function plays an important role in cancer progression, as
well as viral and immune diseases (13). Following the discovery
of two ligand binding pockets (major and minor) of CXCR4,
several drugs targeting this receptor have been studied (14).
With one marketed and others in clinical trials, CXCR4 drugs
receive substantial interest for numerous diseases (15).
Multiple studies using fluorescence-based methods described
CXCR4 oligomerization ranging from expression-dependent
complex formation to stable and ligand-independent CXCR4
homodimers and homooligomers (16, 17). Agonist binding was
proposed to induce conformational changes between the
CXCR4 protomers (18) and even to induce higher-order com-
plexes (19).These agonist-induced CXCR4 nanoclusters were
suggested to define cellular functions of CXCR4, and mutations
that alter the cluster organization also inhibit receptor signaling
in vivo (19). CXCR4 dimerization was also described in malig-
nant cells (20). Moreover, CXCR4 crystal structures with three
different ligands displayed dimeric units with similar interfaces
(21, 22). Although a 1:1 stoichiometry between CXCR4 and its
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main endogenous chemokine ligand, CXCL12, was shown to be
sufficient for signal transduction (23), others reported homomeric
CXCR4 complexes as functionally distinct units (24). Altogether,
there is no clear picture of how and to what extent CXCR4 oligo-
merizes and how oligomerization is modulated. However, such an
understanding would be needed as a basis to define druggable sites
as well as ligands for this clinically important receptor.
Here, we combine advanced microscopy methods—single-
molecule microscopy and fluorescence fluctuation spectroscopy—
to explore the quaternary organization of CXCR4 in living cells, at
different expression levels and both under basal conditions and in
the presence of diverse, chemically distinct CXCR4 ligands. We
observe a transient formation of CXCR4 homodimers, which is
dynamic, depends on expression levels, and is specifically disrupted
by inverse agonists that bind to the minor subpocket of the receptor.
Our data suggest a possible link between receptor dimerization and
the basally active state of CXCR4.
Results
CXCR4 Is Largely Monomeric at Low Expression Levels and Forms
Transient Homodimers. CXCR4 expression in blood cells ranges
from a few thousand to >100,000 receptors per cell [which cor-
responds to ∼4 to >300 receptors per μm2 of membrane area,
assuming a surface area of a T cell at ∼250 μm2 (25)] (26, 27). To
investigate CXCR4 oligomerization at low expression levels, we
used a high spatial resolution method based on total internal
reflection fluorescence microscopy (TIRFM), which allowed us
to resolve and visualize receptors at single-molecule precision
(Fig. 1). For this purpose, we used single images of an
N-terminally SNAP-tagged CXCR4 (SNAP-CXCR4), transiently
transfected in Chinese hamster ovary (CHO) cells and labeled
with SNAP-Surface 549 dye (Fig. 1A). For comparison, SNAP-
β1-adrenergic receptor (SNAP-β1AR) was used as a monomeric
control, and SNAP-CD28 as a constitutively dimeric control, as
described previously (9, 12). Our previous work reported over
90% labeling efficiency using this strategy (28, 29). From indi-
vidual TIRF images (Fig. 1A), we detected single point spread
functions (SI Appendix, Fig. S1) and plotted their intensity dis-
tributions. Mixed Gaussian fitting on these intensity distributions
revealed that, at densities below 0.3 particles per μm2 [which
corresponds to ∼200 receptors per cell, assuming a surface area
of a CHO cell at ∼700 μm2 (30)], SNAP-β1AR was largely mo-
nomeric (94.4% monomeric vs. 5.6% dimeric fraction) (Fig. 1C),
while SNAP-CD28 displayed a 92.6% dimeric and 3.8% tetra-
meric population, with a monomer fraction at 3.6% (Fig. 1D).
For SNAP-CXCR4, we observed mostly monomers (86.7%), an
11.6% dimeric population, and a negligible fraction of higher-
order oligomers (Fig. 1B). These results suggest that SNAP-
CXCR4 exhibits a prevalently monomeric behavior at low con-
centrations in living CHO cells.
Next, we assessed the spatiotemporal dynamics of
CXCR4−CXCR4 interactions by TIRF-based single-particle
tracking. TIRF image series recorded with high temporal reso-
lution (10- to 50-ms time intervals) allowed us to track the lateral
movements of individual single molecules, and thereby to
quantify lifetimes of particle colocalization (Fig. 1E) within the
short observation window that is possible with single-particle
tracking (up to 15 s).
Colocalization events observed in such single-molecule tracks
are composed of specific dimerization events and random
colocalizations (28). Our previous observations from simulated
particles with the diffusion profiles of receptors in the absence of
specific interactions yielded a tau (τ) value of 112 ms for the
lifetime of random colocalizations (29). To distinguish the ki-
netics of random colocalizations from real SNAP-CXCR4
homodimerization events, we fitted a biphasic exponential decay
function to the histogram of dimer lifetimes (Fig. 1F), con-
straining the τ-value of the fast component (representing random
colocalizations) to 112 ms. The resulting slow component
exhibited a τ-value of 890 ms, revealing a component of true
CXCR4−CXCR4 interactions (Fig. 1F). The lifetime of such
dimers is, thus, approximately 2 times longer than that seen for
the largely monomeric μ-opioid receptors (∼460 ms) under
analogous conditions (29).
Overall, these results indicate that, at low expression levels,
SNAP-tagged CXCR4 in living cells are largely monomeric. Such
low expression levels allowed us to observe the dynamics of in-
dividual receptor−receptor interactions, which revealed that the
average lifetime of the few dimers is on the order of 1 s.
Increasing Density Drives CXCR4 toward Homodimers. Having dem-
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Fig. 1. Single-particle tracking analysis reveals dynamic, transient CXCR4
homodimerization. (A) Schematic view of SNAP (red)-CXCR4, labeled with
SNAP-Surface 549 (yellow), and a representative single-molecule TIRFM im-
age in an intact CHO-K1 cell. (B–D) Intensity distributions of SNAP-Surface
549 particles corresponding to (B) SNAP-CXCR4, (C) SNAP-β1AR, and (D)
SNAP-CD28. A mixed Gaussian fit distinguishes fractions of oligomeric pop-
ulations. From the global fit (black line), monomeric (blue), dimeric (green),
and tetrameric (orange) fractions were derived. Intensity values were col-
lected from 27 different cells for SNAP-CXCR4, 8 cells for SNAP-β1AR, and 13
cells for SNAP-CD28 in seven independent experiments. (E) A representative
single receptor track of transient SNAP-CXCR4 homodimerization. Shown
are the coordinates of two SNAP-CXCR4 tracks (blue lines) within an image
series in X (Upper) and Y (Middle) dimensions. Intensity doubling (Lower)
upon particle merging (color change from blue to green) demonstrates re-
ceptor interactions. (F) Distribution of colocalization times obtained from
the length of individual merging−splitting events as in E. A biexponential
decay function (black) with a constrained rate constant (magenta), derived
from simulated randomly colocalizing particles (magenta), resulted in a slow
component (green), representing specific interactions of SNAP-CXCR4, with
a lifetime (τ-value) of 890 (730 to 1,088) ms (mean and 95% CI).


































monomeric with only transient dimerization events, we sought to
investigate how this might change with increasing receptor
densities. Assessing CXCR4 oligomerization at higher levels is of
interest both physiologically and pathologically, since several
cancer cells express high levels [>50,000 CXCR4 molecules per
cell, i.e., >70 receptors per μm2 of membrane area (31, 32)].
TIRFM-based single-particle analysis is limited to low expression
levels, as the spatial separation of individual single molecules is
lost at higher particle densities (29). Therefore, to explore
CXCR4 oligomerization at higher expression levels, we used a
completely different optical approach.
Spatial intensity distribution analysis (SpIDA) (33) is a
fluorescence fluctuation spectroscopy method that calculates
the density and the quantal brightness of fluorescently labeled
molecules from confocal microscopy images. These two values
are used to quantify the average oligomeric state of the protein
of interest. We used a C-terminally EYFP-tagged β1AR as a
monomeric control, as we had confirmed its monomeric be-
havior even at overexpression levels (9, 34). In addition, a β1AR
with two adjacent C-terminal EYFP tags (separated by an
(EAAAK)4 linker) was employed as a “dimeric” control (34)
(Fig. 2A). We performed imaging at the basolateral membranes
of individual HEK293AD cells expressing the respective fluo-
rescently labeled constructs. For image analysis, we avoided
selecting large membrane regions, as well as areas with het-
erogeneous fluorescent distributions, which are not associated
with true receptor oligomers (Fig. 2A) (35). SpIDA analysis of
controls revealed that the brightness values obtained for β1AR-
2xEYFP were twice those of β1AR-EYFP (Fig. 2B). At differ-
ent expression levels ranging from 15 to 120 molecules per μm2
of membrane area, these brightness values remained constant
(Fig. 2C).
Stepwise photobleaching with SpIDA further confirmed the
reliability of our control constructs: If a particular fluorescently
labeled protein is truly monomeric, photobleaching will decrease
the number of fluorescent particles, without affecting their
brightness (33). SpIDA, after photobleaching of β1AR-EYFP,
showed that the brightness did not change even after 10 frames,
although the density of fluorescent particles decreased (SI Ap-
pendix, Fig. S2 A and B). This confirms again the monomeric
character of β1AR-EYFP. For β1AR-2xEYFP, we observed a
decrease in brightness in parallel with a decrease in their number
(SI Appendix, Fig. S2 C and D).
Having established these controls, we then focused on
CXCR4. Since HEK293 cells have been reported to express
endogenously very low levels of CXCR4 (36), we first assessed
the endogenous levels of CXCR4 in our specific HEK293AD cell
line, using a fluorophore conjugated antibody that recognizes a
specific epitope on CXCR4 (SI Appendix, Fig. S3A). We ob-
served a fluorescence signal from the antibody in CXCR4-ECFP
transfected cells, but not in control cells (SI Appendix, Fig. S3B).
This indicates endogenous CXCR4 expression in our
HEK293AD cell is below the detection limit of our SpIDA ap-
proach (less than five receptors per square micrometer of
membrane area).
SpIDA revealed a density-dependent dimerization profile of
CXCR4-EYFP (Fig. 2C). We observed brightness values be-
tween the monomeric and the dimeric controls within the range
of 10 to 30 receptors per μm2 density [7 to 20,000 receptors per
cell, assuming a surface area of a HEK293 cell at 700 μm2 (37)]
(SI Appendix, Fig. S2E). Analysis within the range of 85 to 150
receptors per μm2 (60,000 to 105,000 receptors per cell) resulted
in an average oligomeric state corresponding to that of the di-
meric control (SI Appendix, Fig. S2F), pointing out a concen-
tration dependence of CXCR4 dimers. To quantify this
concentration dependence, we binned CXCR4-EYFP oligomeric
state values obtained from SpIDA (Fig. 2C). Combining these
results with those observed in single-molecule analyses, we
calculated that CXCR4 dimerizes with a dissociation constant of
about 30 molecules per μm2 (Fig. 2D). This analysis also reveals
that CXCR4 is mainly dimeric at oncogenic expression levels
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Fig. 2. SpIDA analysis reveals density-dependent formation of metastable
CXCR4 dimers. (A) Schematics of the monomer (β1AR-EYFP)/dimer (β1AR-
2xEYFP) controls (EYFP as yellow balls), with their representative basolateral
membrane confocal images. Homogeneous membrane areas (gray polygons
as ROIs) were analyzed. (B) Representative fluorescence intensity distribution
(obtained from images as in A; dark gray for β1AR-EYFP and light gray for
β1AR-2xEYFP) with Super-Poissonian fitting to calculate number (N) and
brightness («). (C) Measured average oligomeric state per cell as a function
of fluorescent particle number. Each data point represents the brightness
value obtained from a single cell, normalized to the average brightness of
the monomeric control β1AR-EYFP. (D) Binned average oligomeric state
values from single molecule (filled gray circle) and SpIDA data (open white
circles) as a function of receptor number per square micrometer of mem-
brane area, with SD on both axes. A sigmoidal curve (dark gray) fitting
yielded the dimer dissociation constant of 33.6 (27.5 to 39.6) receptors per
μm2 (mean and CI). The fitted line saturated at 2.21 (1.97 to 2.39) (mean and
CI). The shaded pink area marks the range of oncogenic CXCR4 levels (as
observed in refs. 31 and 32). (E) Schematics of the dimer dilution SpIDA:
SNAP-CXCR4 dimerization with CXCR4-EYFP (Top Right, EYFP as yellow ball,
SNAP tag as red) results in lower « than a CXCR4-EYFP homodimer (Top Left).
Representative images of HEK293AD cells coexpressing CXCR4-EYFP (Bottom
Right, gray) + SNAP-CXCR4 labeled with SNAP-Surface 647 (Bottom Right,
red), and CXCR4-EYFP (Bottom Left, gray) + empty vector as negative con-
trol. (F) SpIDA on HEK293AD cells coexpressing β1AR-EYFP + vehicle (dark
gray), β1AR-EYFP + SNAP-β1AR (light gray), CXCR4-EYFP + empty vector
(yellow) and CXCR4-EYFP + SNAP-CXCR4 (red). The data are displayed with
mean ± SD from three independent experiments.


























Some fluorescent proteins have been described to self-assemble
within cellular compartments (38). Therefore, we tested whether
the observed CXCR4-EYFP dimers are a result of EYFP self-
assembly or true CXCR4 homointeractions. To do so, we ap-
plied a different labeling strategy by using an N-terminal SNAP-
tagged CXCR4 (SNAP-CXCR4), labeled with SNAP-Surface
Alexa Fluor 488 dye, and performed SpIDA in intact cells.
Again, SNAP-β1AR served as a monomeric control. Also with this
label, CXCR4 exhibited an expression-dependent dimerization
profile, comparable to that seen with CXCR4-EYFP (SI Appendix,
Fig. S2G). This confirms that the dimeric organization of CXCR4-
EYFP is truly mediated by receptor interactions, and not due to
nonspecific fluorescent protein interactions.
We also tested whether the density dependence of dimeriza-
tion could be reproduced in a different cellular context. In
agreement with published data (39), we did not detect any en-
dogenous CXCR4 in our in CHO cells with a fluorophore-
conjugated antibody (SI Appendix, Fig. S3 C and D). This
allowed us to perform SpIDA in intact CHO cells, which were
transiently transfected with EYFP-tagged CXCR4. We again
observed a concentration-dependent fashion of CXCR4 dimer-
ization (SI Appendix, Fig. S2H), supporting the data obtained in
HEK293AD cells.
CXCR4 dimerization at high density was further confirmed by
coexpressing an N-terminally SNAP-tagged CXCR4 with CXCR4-
EYFP (Fig. 2E). As expected, coexpression of SNAP-CXCR4
resulted in a reduced CXCR4-EYFP dimerization, as evidenced
from a decreased EYFP brightness, indicating that the SNAP-
tagged CXCR4 competed with CXCR4-EYFP in their dimeriza-
tion (Fig. 2F). In cells cotransfected with CXCR4-EYFP and
empty vector, the dimeric CXCR4 behavior remained intact
(Fig. 2F). As a control for a monomeric behavior, we showed that
expressing SNAP-β1AR with β1AR-EYFP did not affect β1AR-
EYFP brightness noticeably, as to be expected, given that β1AR-
EYFP exhibits an essentially monomeric distribution (Fig. 2F).
Together, these results suggest that CXCR4-EYFP shows
density-dependent dimerization, making it at oncogenic expres-
sion levels a pure dimer.
Selective Antagonists of CXCR4 Can Disrupt CXCR4 Dimerization with
Different Efficacies. We next assessed whether ligands targeting
CXCR4 can modify the receptor dimerization. Using SpIDA in
intact HEK293AD cells at levels where the CXCR4-EYFP is
prevalently dimeric (>50 molecules per μm2), we first tested the
endogenous CXCR4 agonist, CXCL12. Within 1 min, 100 nM
CXCL12 did not alter the dimeric stoichiometry substantially
(Fig. 3A). At later time points, CXCR4-EYFP formed clusters
(SI Appendix, Fig. S4A) that colocalized with clathrin-associated
adaptor protein AP2 subunit μ2 (SI Appendix, Fig. S4C). Tem-
poral kinetics of cluster formation and receptor internalization
by CXCL12 were in good correlation (SI Appendix, Fig. S4 D and
E) and were preceded by β-arrestin2 recruitment kinetics (SI
Appendix, Fig. S4F).
We then tested antagonists with distinct chemical and structural
properties: the bicyclam small-molecule antagonists AMD3100
and AMD3465, the T140 derivative peptide TC14012, the iso-
thiourea derivative small-molecule IT1t, the cyclic peptides
LY2510924 and FC131, and the nanobody VUN401 (40). Results
with the antagonists displayed distinct profiles: AMD3100 and
AMD3465 did not change the basal CXCR4 stoichiometry, and
TC14012 induced only a slight decrease (Fig. 3A and SI Appendix,
Fig. S5 A–C and Table S1). In contrast, LY2510924 and IT1t
produced a significant decrease (Fig. 3A and SI Appendix, Fig.
S5 D and E). Moreover, FC131 and VUN401 disrupted CXCR4-
EYFP dimers completely at varying expression ranges (Fig. 3A
and SI Appendix, Fig. S5 F and G and Table S1).
To understand how fast the new monomeric state can be
reached, we then evaluated the kinetics of dimer destabilization
induced by FC131 and IT1t using SpIDA. This analysis revealed
that dimer destabilization starts within the first 30 s of FC131
treatment and equilibrates to the monomeric state with a tau
(τ)-value of 50 s (30 to 84 CI), while IT1t-mediated destabili-
zation occurs with τ = 46 s (30 to 72 CI). The nanobody VUN401
displayed a rapid disruption of dimers, with τ = 17 s (0 to 50 CI)
(Fig. 3B).
We also tested the dimer disrupting effect of the ligands using
a temporal brightness (TB) approach commonly referred to as
the number and brightness method (41, 42). The results from this
assay accurately reflected those obtained by SpIDA analysis
(Fig. 3C).
To rule out that our SpIDA-based oligomerization analyses
might be influenced by receptor clustering or binding to heter-
ologous interaction partners, which may not be associated with
specific receptor−receptor interactions, we performed a careful
area selection in our measurements (35). Furthermore, as a
conceptually independent control that reports direct protein−-
protein interactions at the nanometer scale, we performed
fluorescence resonance energy transfer (FRET) acceptor pho-
tobleaching (FRET AB). For CXCR4 in its basal state, we ob-
served a hyperbolic increase of FRET efficiency with increasing
A B
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Fig. 3. CXCR4 antagonists modulate receptor dimerization with distinct
profiles. (A) SpIDA analysis of HEK293AD cells expressing β1AR-EYFP (dark
gray) and CXCR4-EYFP (yellow) and CXCR4-EYFP after 20 min of incubation
with ligands: 10 μM AMD3100 (purple), 10 μM AMD3465 (gray), 10 μM
TC14012 (green), 100 nM LY2510924 (dark gray), 10 μM IT1t (blue), 10 μM
FC131 (red), and 1 μM VUN401 (pink). Each data point represents a bright-
ness value from one cell normalized to the monomer control, given with
mean ± SD as error bars. Data were obtained from at least three experi-
ments per condition. Statistical tests and multiple comparisons of conditions
are provided in SI Appendix, Table S1. (B) SpIDA kinetics of dimer destabi-
lization by VUN401, IT1t, and FC131. Different cells were imaged for SpIDA
analysis for 20 min at 30-s intervals upon ligand addition. Plotted values over
time were fitted to a monoexponential decay function. The data represent
mean ± SD of three independent experiments. (C) Correlation of average
oligomeric states (with SD) obtained from SpIDA (x axis) and TB measure-
ments (y axis). Color coding of the data points is the same as in A. Black
straight line is the linear fit of the data (slope: 0.94 [0.873 to 1.014 CI]),
representing the degree of correlation for two methods. (D) FRET acceptor
photobleaching experiment in HEK293AD cells coexpressing CXCR4-ECFP
and CXCR4-EYFP. Each data point is obtained from a single cell. Color coding
of the data points is the same as in A.


































EYFP intensity, indicating specific interactions between CXCR4-
ECFP and CXCR4-EYFP. In the presence of LY2510924, we also
observed a hyperbolic behavior, but with lower FRET efficiency
and a lower dissociation constant (Kd =20,587 intensity units, IU)
than that for CXCR4 alone (Kd = 700 IU), indicating decreased
CXCR4 homodimerization. FC131, IT1t, and VUN401 also re-
duced FRET efficiencies and resulted in a linear FRET increase
(Fig. 3D), indicating unspecific receptor−receptor interactions.
Altogether, these results suggest that the CXCR4 dimerization
is specific, and that it can be modulated in a ligand-specific
manner. LY2510924 binding moderately decreased CXCR4 di-
merization, while IT1t, FC131, and VUN401 disrupted it com-
pletely, and the average stoichiometry became monomeric in
ensemble measurements.
CXCR4 Dimerization Is Linked with Receptor Activity. Having ob-
served that certain antagonists can disrupt CXCR4 dimers, we
questioned whether this spatial rearrangement is linked to re-
ceptor activity. First, we measured G protein activation by
CXCR4, using a FRET-based Gi2 protein activation biosensor
(43), for which a decrease in FRET reports Gi protein activation.
With the agonist CXCL12, we observed a 13% decrease in
FRET, indicating Gi2 sensor activation. Compared to the buffer
control, AMD3100, AMD3465, and VUN401 did not induce any
major FRET change. TC14012 induced a small increase.
LY2510924, IT1t, and FC131 produced a much higher increase,
pointing out a certain level of basal Gi2 activation that was sig-
nificantly reversed by these three ligands (Fig. 4A and SI Ap-
pendix, Table S2). To assess the degree of this basal Gi2 activity
in CXCR4-expressing cells, we treated cells with Pertussis toxin
(PTx), an inhibitor of Gi2 activity. This treatment resulted in a
5% higher FRET signal of the Gi2 sensor, which indicates the
span of the FRET change induced by CXCR4 basal activity
(Fig. 4A; see also Fig. 6B).
Using the same experimental setup, we tested whether these
ligands can also modulate G protein signaling triggered by a
constitutively active mutant (CAM) of CXCR4, produced by
mutating Asp119 to Ser (N1193.35S) (44). We detected a lower
basal FRET ratio of the Gi2 sensor with this mutant compared to
the wild-type (WT) CXCR4, indicating further constitutive ac-
tivity of CXCR4 N1193.35S mutant (SI Appendix, Fig. S6A). With
CXCR4 CAM, CXCL12 and AMD3100 further decreased the
FRET signal by the Gi2 sensor. AMD3465 produced a minor
increase. TC14012, LY2510924, IT1t, and FC131 induced a
significant FRET increase, while VUN401 induced no FRET
change (SI Appendix, Fig. S6B and Table S2). These experiments
showed that TC14012 acts as an efficient inverse agonist on the
CAM CXCR4, but its effect on the WT receptor is only minor.
LY2510924, FC131, and IT1t are inverse agonists of both the
WT and the CAM CXCR4, as seen at the G protein level.
To further understand the downstream effects of CXCR4 li-
gands, we employed a bioluminescence resonance energy trans-
fer (BRET)-based assay in 96-well plate format. We measured
interactions between C-terminally nanoluciferase-tagged CXCR4
(CXCR4-nLuc) and C-terminally SYFP tagged Gγ2 subunit (Gγ2-
SYFP), transfected together with the Gαi2 and Gβ1 subunits for
proper G protein stoichiometry. With the agonist CXCL12, we
observed a concentration-dependent decrease in BRET. In con-
trast, except AMD3100 and AMD3465, all other ligands exhibited
a concentration-dependent increase in BRET (Fig. 4B). Surpris-
ingly, despite having no effect on the G protein activity, in the
BRET assay, the nanobody VUN401 displayed the largest efficacy
and potency among all antagonists (SI Appendix, Fig. S6C), fol-
lowed by FC131, LY2510924, and IT1t.
The nanobody displayed its monomerizing effect also on the
CAM CXCR4, yet without changing the activity of this mutant,
even though FC131 still retained its ability to reduce both
constitutive activity and dimerization also in this mutant (SI
Appendix, Fig. S7).
Overall, there was a clear correlation (R = 0.77) between the
effects of the various ligands on G protein activation (as assessed
by the Gi2 sensor) and on the dimerization behavior of the
CXCR4 (Fig. 4C). Fitting a linear regression resulted in a nearly
identical slope (m = 0.011 [0.010 to 0.012 CI]) with a pseudo-
correlation (m = 0.010) where we assumed that zero basal ac-
tivity corresponds to monomeric CXCR4 and 100% basal activity
to dimeric receptor. While all small-molecule ligands were al-
most perfectly placed on the correlation line, the nanobody
VUN401 was a clear exception, since it almost completely pre-
vented dimerization but did not affect basal activity (Fig. 4C).
Following these observations, we asked whether the presence
of the heterotrimeric G protein or β-arrestin contributes to
CXCR4 dimerization. We performed SpIDA analysis of
CXCR4-EYFP in HEK293 cells in which all genes encoding for
functional Gαs, Gαq, GαI, and Gα12/13 proteins (ΔGα
HEK293) or β-arrestin1/2 (Δβarr HEK293) are knocked out by
genome editing. In these cells, we again observed a dimeric
CXCR4 behavior, and FC131, IT1t, and VUN401 were still able
to disrupt CXCR4 dimers efficiently (SI Appendix, Fig. S8). This
indicates that CXCR4 homodimers are stabilized neither by
heterotrimeric G proteins nor by β-arrestins.
Distinct Ligand Binding Modes Correlate with Their Dimer Destabilization.
Intrigued by the ability of CXCR4 inverse agonists to disrupt di-
mers and reverse the receptor basal signaling, we asked whether
distinct ligand binding modes might explain these newly discov-
ered effects. To understand this, we determined the binding poses
of all experimentally tested ligands on the CXCR4 crystal struc-
ture (21) based on experimentally validated mutation and struc-
ture−activity relationship data from the literature (see Materials
and Methods for references). As a result, we obtained specific
binding poses of all tested ligands (Fig. 5A). Our approach showed
that the residues on CXCR4 that interact with ligands clustered
into the transmembrane major and minor binding pockets (45),
and the extracellular domain of CXCR4 (Fig. 5C).
In contrast to the distinct extracellular binding of the nano-
body VUN401 (Fig. 5B) (40), all of the other antagonists interact
essentially with the transmembrane binding pocket. Among
these, AMD3100 (Fig. 5D and SI Appendix, Fig. S9A), AMD3465
(Fig. 5E and SI Appendix, Fig. S9B), and TC14012 (Fig. 5F and
SI Appendix, Fig. S9C) bind exclusively to the major pocket, all
specifically interacting with the acidic residues Asp1714.60 (TM4)
and Asp2626.58 (TM6). All ligands that reduce the receptor di-
merization and basal activity display a common binding mode
that is different from that of AMD3100, AMD3465, and
TC14012: IT1t (Fig. 5H) was found prevalently in the minor
binding pocket, forming interactions with the TM2 residues
Trp942.60, Asp972.63, and Tyr1163.32 (SI Appendix, Fig. S9E).
FC131 was accommodated between the major and minor pocket
(Fig. 5G) with its L‐Arg2 residue extending toward the minor
pocket (SI Appendix, Fig. S9D) to form an ionic contact with
Asp972.63 (TM2) and a cation−pi interaction with Tyr1163.32.
Generation of an experimentally validated binding pose of
LY2510924 was not possible, due to a lack of mutation data in
the literature to guide and prioritize structural models (com-
pared to the rest of the ligands reported in this manuscript).
However, LY2510924 was previously reported to possess an ex-
tended binding mode (46); it interacts with residues in the major
pocket (Asp18745.51, Arg18845.52, Tyr19045.54, and Gln2005.39)
and extends toward the minor pocket via interactions with
His1133.29 and Glu2887.39 (SI Appendix, Fig. S9F).
To test experimentally whether the minor pocket binding in-
deed plays a role in modulating receptor dimerization, we mu-
tated the minor pocket residue tyrosine (Y) 116 to serine (S)
(Y1163.32S), as this residue is critical for FC131 and IT1t binding


























(21, 47). Then, we assessed the oligomeric state of this mutant
using SpIDA. At densities above 60 molecules per μm2 mem-
brane area, Y1163.32S displayed a highly dimeric behavior. While
100 nM IT1t or FC131 were able to disrupt dimerization of WT
CXCR4, these ligands were remarkably less efficient in desta-
bilizing the Y1163.32S dimers (SI Appendix, Fig. S9G).
In conclusion, our docking and experimental data reveal
common binding features for the ligands that support their dimer
destabilizing ability. While the antagonists that form contacts
with minor pocket residues (IT1t, LY2510924, and FC131) are
effective in breaking CXCR4 homodimer formation, those that
bind entirely to the major pocket do not disrupt these dimers.
TM6 Mutations Attenuate CXCR4 Basal Activity and Dimerization.
Having observed that the basally active CXCR4 forms dimers,
and that inhibition of basal activity correlates with disruption of
dimers, we sought to understand the molecular mechanisms
mediating this behavior. We thus focused on the transmembrane
residues that control the conformational switch of CXCR4 (48).
Among these, the TM6 residues valine (V) 2426.38 and leucine
(L) 2466.42 reside in the center of the conserved signaling motifs
of GPCRs (Fig. 6A), and have been proposed to regulate the
microswitches that activate CXCR4 (48) via interactions with
side chains of TM helices 5, 6, and 7. Therefore, we generated a
V242 to aspartate mutant (V2426.38D) and L246 to proline
(L2466.42P) to abolish signaling of CXCR4. The V2426.38D mu-
tation converted CXCR4 from an exclusively dimeric to an ex-
clusively monomeric state (Fig. 6B). Moreover, this mutant
markedly reduced the basal Gi activity (visible from an increased
basal FRET ratio of the Gi2 sensor) (Fig. 6C), and displayed no
response to any ligand in the Gi activation assay (SI Appendix,
Fig. S10A). Similarly, L2466.42P also displayed a markedly re-
duced dimeric behavior (Fig. 6B). This mutant also displayed a
reduced basal activity on the G protein assay, yet to a lesser
extent compared to the V2426.38D mutant. In line with this, the
partial basal activity of the L2466.42P mutant was further
inhibited by IT1t and FC131 (SI Appendix, Fig. S10B).
When we compared the extent of basal activity and oligomeric
state of these mutants with the WT CXCR4, we again observed a
notable positive correlation between the basal activity and re-
ceptor stoichiometry of our TM6 mutants (R = 0.7), further
confirming the relationship between these two features
(Fig. 6D).
Together, these results demonstrate that the V2426.38D mu-
tation induces a CXCR4 conformation, which no longer activates
Gi basally, and is unresponsive to any ligand. In contrast to the
WT receptor, this mutant presents an essentially monomeric
organization. This supports the importance of basal activity of
the CXCR4 for its dimerization. Also, the degree of reduction in
the basal activity and dimerization in L2466.42P mutant corrob-
orate the positive correlation between the basal activity and di-
merization of CXCR4.
Discussion
Growing evidence indicates that several class A GPCRs can form
dimers and oligomers, but the molecular mechanisms that me-
diate their oligomerization and the downstream effects are
poorly understood. Here, we studied the biophysical dynamics
and conformational implications of CXCR4 membrane organi-
zation at expression levels ranging from ∼200 to ∼100,000 re-
ceptors per cell. Cells relevant for physiological CXCR4
functions express from a few thousands to 150,000 copies of
CXCR4 (26, 49), while metastatic breast cancer cells express
above 100,000 CXCR4 copies per cell (31). At the low expres-
sion levels that are required for single-molecule experiments,
CXCR4 was found to be mainly monomeric, but individual
CXCR4 receptors formed transient homodimers. Their lifetimes


















































































FRET BRET: CXCR4-nLuc + Gγ2-SYFP













Fig. 4. CXCR4 constitutively activates Gi2. (A) (Top) Schematics of the FRET based Gi2 activation measurement. Gi2 sensor is in the high FRET conformation at
the resting state. CXCL12 binding to CXCR4 induces a lower FRET state of the sensor. (Bottom) FRET changes in the Gi2 sensor by CXCR4 ligands. Scatter dot
plots with bars show average FRET changes 20 min after the addition of different ligands. The dotted gray line represents the average ΔFRET resulting from
PTx treatment. Error bars represent SD of at least four independent experiments. Statistical significance analysis is provided in SI Appendix, Table S2. (B) (Top)
Schematics of the BRET measurement between CXCR4-nLuc and Gγ2-SYFP. At the basal state, CXCR4-nLuc and Gγ2-SYFP are at BRET distance. CXCL12 binding
to CXCR4-nLuc results in a decrease in BRET. (Bottom) Concentration−response curves obtained by fitting the data to a four-parameter Hill equation.
Obtained pEC50 values: CXCL12: 9.5 (9.7 to 9.3 CI); LY2510924: 8.1 (8.2 to −7.9 CI); TC14012: 7.7 (8.0 to 7.3 CI); IT1t: 7.8 (8.3 to 5.7 CI); VUN401: 7.9 (8.3 to 6.6 CI).
Data points at each concentration show the mean ± SD from at least three independent plate reader experiments. (C) Correlation plot of basal activity and
oligomeric state; oligomeric state values were obtained from the data given with SD error bars in Fig. 3A. Basal activity data (with SD error bars) was
generated by normalizing the data in A to % ΔFRET of PTx (as 0%) and vehicle treatment (as 100%). The dotted line shows the assumed pseudocorrelation,
and the black line is the actual fit (VUN401 was identified as an outlier; SI Appendix, Table S3) with 95% CI (in gray).


































D2 dopamine receptors (50), but in agreement with those of the
neurotensin 1 receptor (NT1R), which exhibits a dynamic and
density-dependent dimerization (51). Much like the NT1R,
CXCR4 homodimers also became prevalent with increasing re-
ceptor expression. However, the essentially fully dimeric nature
of CXCR4 at higher expression levels suggests the existence of
dimers with far longer half-lives than can be observed in single
particle tracks, as has been suggested for agonist-stimulated
μ-opioid receptor dimers (29). The highly dimeric nature of
CXCR4 at densities >50,000 receptors per cell (>70 receptors
per μm2 membrane) might as well represent the scenario of
CXCR4 organization in oncogenic cells. Yet, it should be noted
that CXCR4 is expressed in diverse tissues, and the receptor’s
membrane organization may be significantly influenced by dif-
ferent cellular contexts and the abundance of interaction
partners (52).
Agonist (CXCL12) stimulation apparently further induces
dimerization, but this is difficult to differentiate from subsequent
agonist-induced clustering that leads to CXCR4 internalization.
We observed that CXCR4 remains dimeric within 1 min after
agonist-mediated activation. This supports our recent observa-
tion of a rapid dimeric rearrangement upon activation, rather
than a shift in oligomer stoichiometry (53). Moreover, the di-
meric stoichiometry of CXCR4 within the time that is needed for
full G protein activation (53) also suggests that the agonist-
bound CXCR4 dimer is conformationally distinct from the
basal dimers.
The dimeric CXCR4 nature appears to be closely linked to its
known basal activity (53, 54). In contrast to AMD3100 and
AMD3465, that are exclusive major pocket binders, LY251092,
IT1t, and FC131, ligands that bind entirely or partially the minor
pocket of CXCR4, efficiently reduced basal activity and also
disrupted receptor homodimers. Furthermore, the slight inverse
agonism of TC14012 correlates with its lack of efficiency in
disrupting CXCR4 dimers. Thus, minor pocket ligands, which
presumably affect critical residues that are required to initiate
CXCR4 signaling (48), inhibit both basal activity and dimer
formation. The decreased dimer disruption abilities of FC131
and IT1t in the Y1163.32S mutant support the importance of
minor pocket binding to modulate receptor dimerization. Alto-
gether, we observed a positive correlation between CXCR4 basal
activity and dimeric organization. In line with this, the CXCR4
V2426.38D mutant which exhibits virtually no basal activity is
monomeric, supporting the notion that the basally active re-
ceptor conformation essentially mediates dimerization. More-
over, low basal activity and decreased dimeric organization of the
L2466.42P mutant also supports that the degree of basal activity
determines the degree of CXCR4 dimerization. CXCR4 di-
merization in the absence of functional G proteins or of
β-arrestin1/2 corroborates that the dimerization is an intrinsic
VUN401
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Fig. 5. Binding modes of different CXCR4 ligands are connected with their ability for dimer destabilization. (A) Overview of the CXCR4 crystal structure (PDB
ID code 3OE0, gray cartoon) with docked VUN401 (magenta), TC14012 (green), AMD3100 (purple), FC131 (brown), CXCL12 (yellow), and IT1t (cyan), seen
detailed in B and D–G. Ligand docking was based on the data displayed in SI Appendix, Fig. S9. (B) Zoom-in view of the transmembrane domain binding site of
CXCR4, where no VUN401 interactions are observed. VUN401 binds in view of the extracellular vestibule of CXCR4 and its epitope has been matched to the
residue R30 in the CXCR4 N terminus. (C) Top view of the CXCR4 transmembrane domain binding site, which can be divided into a minor pocket comprising
TM1-3 and TM7 (rose), and a major pocket, comprising TM3-7 (purple). The side chains of residues that have been experimentally validated to interact with
CXCR4 ligands are presented in sticks in all binding mode representations. (D–H) Binding mode representations based on literature data of (D) AMD3100, (E)
AMD3465, (F) TC14012 (based on cocrystallized ligand CVX-15), (G) FC131, and (H) IT1t. Images were placed from left to right to visualize the binding pose
shift from major to minor pocket. (I) Overview of the CXCR4 residues that are in contact with ligands. (For references, see Materials and Methods.) Individual
residue−ligand atomic interactions are summarized in SI Appendix, Fig. S9.


























feature of basal as well as agonist-induced active receptor con-
formations. This is in line with the recent observations that class
A GPCRs can adopt an active conformation and display intrinsic
activity even in the absence of G proteins (55–57).
In contrast, if dimerization is prevented by a steric hindrance
by the use of the nanobody VUN401, which binds to the extra-
cellular domains of CXCR4 and does not reach the major or
minor subpockets, the receptor activity is not affected. This in-
dicates that mechanical disruption of CXCR4 dimerization alone
does not translate into changes in activity. Therefore, CXCR4
dimerization is a consequence of its basal activity, and inhibition
of CXCR4 basal activity leads to dimer disruption.
Moreover, the observation that the nanobody VUN401 does
not affect basal activity, yet alters the interaction between
CXCR4 and G proteins (as evidenced from the CXCR4/Gγ2
BRET assay), implies that there may be different ways CXCR4
dimers and monomers interact with G proteins that result in
similar extents of basal activity.
Developing efficacious CXCR4 antagonists is of major clinical
interest (14). Ligands targeting the minor pocket of CXCR4 (58)
or diminishing the CXCR4 basal activity have been reported to
effectively reverse inflammation in vivo (59). This highlights how
the binding mode and signaling outcome of CXCR4 ligands may
determine their effectiveness in pathologies. Therefore, it would
be interesting to further clinically evaluate those CXCR4 ligands
that specifically bind to the minor pocket, act as inverse agonists,
and disrupt receptor dimers. The common binding motifs in the
minor pocket observed for the dimer-destabilizing ligands may,
thus, serve as a scaffold to develop more potent and efficient
inhibitors of CXCR4 activity as well as dimerization.
Materials and Methods
Materials. AMD3100 was purchased from Sigma-Aldrich. AMD3465, TC14012,
and FC131 were from Tocris Bioscience. LY2510924 was from MedChemEx-
press. Human recombinant CXCL12 was from Peprotech. SNAP-Surface 549,
SNAP-Surface Alexa Fluor 488, and SNAP-Surface Alexa Fluor 647 were
purchased from New England Biosciences. Alexa Fluor 488 conjugated
CXCR4 antibody (#44717, FAB173G) was purchased from R&D Systems.
Molecular Biology. The CXCR4 complementary DNA (cDNA) sequence was
provided in pcDEF3 vector plasmid through the Oncogenic GPCR Network of
Excellence and Training (ONCORNET) consortium from Vrije Universiteit
Amsterdam. In order to generate a CXCR4-encoding pcDNA3 expression
construct, the CXCR4 sequence was digested from the pcDEF3 construct
using the restriction enzymes EcoRI and XbaI and ligated into pcDNA3 vector
that was digested using the same restriction enzymes. To generate
pcDNA3-SNAP-CXCR4 expression construct, the CXCR4 sequence was PCR
amplified using the primers 5′-CTAGCTAGCGATGAGGGGATCAGTATATA-3′
(forward) and 5′-CCCTCGAGTTAGCTGGAGTGAAAACTTGAA-3′ (reverse) and
digested using the restriction enzymes NheI and XhoI. The digested frag-
ment was ligated in frame with a SNAP encoding sequence in the previously
described pcDNA3-SNAP construct. To generate pcDNA-CXCR4-EYFP ex-
pression construct, the CXCR4 encoding sequence was PCR amplified using
the following primers: 5′-AAAGAATTCATGGAGGGGATCAGTATATACAC-3′
(forward) and 5′-AAATCTAGAGCTGGAGTGAAAACTTGAAGA-3′, and the
amplified fragment was digested using the restriction enzymes EcoRI and
XbaI, and then subsequently cloned in a previously described pcDNA3-
beta2AR-EYFP construct in frame with EYFP encoding sequence. To generate
pcDNA-CXCR4-nLuc expression construct, nLuc encoding sequence (pur-
chased from Promega) was PCR amplified 5′-AAATCTAGA GTCTTCACACTC-
GAAGATTTCGTTGGGGAC-3′ (forward) and 5′-AAAGCGGCCGC TTACGCCAG-
AATGCGTTCGCACAG-3′ (reverse) and digested using the restriction enzymes
XbaI and NotI. The digested nLuc fragment was ligated in the pcDNA3-
CXCR4-EYFP construct, replacing EYFP. Y1163.35S, N1193.35S, V2426.38D, and
L2466.42P mutants were generated using the Q5 Site-Directed Mutagenesis
Kit (New England Biomedicine) with the following primers: 5′-CCATGTCAT-
CTCCACAGTCAACC-3′ and 5′- ACTGCCTTGCATAGGAAG-3′ (Y1163.35S); 5′-
CTACACAGTCtctCTCTACAGCAGTG-3′ and 5′-ATGACATGGACTGCCTTG-3′
(N1193.35S); 5′-CAAGACCACAgacATCCTCATCCTGG-3′ and 5′-AGGGCCTTG-
CGCTTCTGG-3′ (V2426.38D); 5′-CATCCTCATCCCAGCTTTCTTCGCCTG-3′ and 5′-
ACTGTGGTCTTGAGGGCC-3′ (L2466.42P).
Gi2 sensor (pGβ1-2A-cp173Venus-Gγ2-IRES-Gαi2-mTurquoise2Δ9) was a
gift from Dorus Gadella, University of Amsterdam, Amsterdam, the Neth-
erlands (Addgene plasmid #69624). AP2μ2-mCherry was a gift from Christien













































































































Fig. 6. CXCR4 V2426.38D and the L2466.42P mutants are monomeric and display no basal or ligand-induced activity. (A) (Left) Position of the V2426.38 residue
on CXCR4 model (68). V2426.38 interacts with other TM6 residues (shown as sticks) and forms a hydrophobic network that stabilizes the microswitch residues
on TM5 and TM7 (shown as sticks), viewed from side (Middle) and top (Right). (B) SpIDA shows that the V2426.38D mutant (light gray) is mainly monomeric and
the L2466.42P is largely monomeric in comparison to the WT CXCR4 (yellow). (C) V2426.38D and L2466.42P mutants display higher basal FRET ratios (lower basal
G protein activity), in comparison to the WT CXCR4 (yellow) on FRET-based Gi2 sensor. PTx-induced increase in FRET probes the basal activity of CXCR4. (D)
Correlation plot of basal activity and oligomeric state for the TM6 mutants; data with SD error bars were derived from B and C. The dotted line indicates the
pseudocorrelation. The black line with 95% CI (gray shades) is the actual fit (slope m = 0.009 [0.008 to 0.010 CI]).


































Cell Culture. HEK293AD cells (BioCat) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (PAN Biotech) supplemented with 10% (vol/vol)
fetal bovine serum (FBS) (Biochrom AG), 1% L-glutamine (PAN Biotech),
penicillin (100 U/mL), and streptomycin (100 μg/mL) at 37 °C and 5% CO2.
CHO cells (ATCC CCL-61) were cultured in phenol red-free DMEM/F12 (Gibco)
supplemented with 10% FBS (Biochrom AG), 1% L-glutamine (PAN Biotech),
100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C and 5% CO2. To
passage cells, medium was aspirated, and cells were washed once with 5 mL
of phosphate-buffered saline (PBS) (Sigma-Aldrich), followed by a second
wash with trypsin 0.05%/(ethylenedinitrilo)tetraacetic acid 0.02% in PBS for
1 min, then resuspended in DMEM (for HEK293AD cells) or DMEM/F12 (for
CHO-K1 cells).
TIRFM Imaging. For single-molecule imaging experiments, CHO-K1 cells were
grown on glass coverslips in six-well plates 24 h prior to transfection. Cells
were transfected with 2 μg of SNAP-tag incorporated receptor vector using
Lipofectamine 2000 (Thermo Fisher Scientific) as previously described (28)
and incubated for 4 h to 6 h at 37 °C and 5% CO2. Transfected cells were
labeled using 1 μM SNAP-Surface 549 dye in complete DMEM/F12 medium
for 20 min. Cells were then washed three times with 5-min incubation in
complete culture medium after each wash. Coverslips with labeled cells were
placed in an Attofluor cell chamber (Thermo Fisher Scientific) and supple-
mented with Hank’s Buffered Saline Solution (HBSS). TIRF imaging was
performed using a commercial TIRF illuminated Nikon Eclipse Ti2 inverted
microscope (Nikon) equipped with a beam splitter connected to four sepa-
rate electron multiplying-charge coupled device (EM-CCD) cameras (Andor
iXon Ultra897), a CFI Apochromat 100× 1.49 TIRF objective with automated
correction collar, a laser box with four laser diode lines (405, 488, 561, and
647 nm) coupled through an automated module, and an automated
infrared-guided autofocus system. Imaging was performed at constant 20 °C
ambient and objective temperature, with continuously active autofocus
module. Single TIRF images for intensity analysis were captured with 40-ms
acquisition time at 100% laser power. To determine dimerization kinetics,
laser illumination was focused to the center of the imaging field by 2× via
Nikon-Stochastic Optical Reconstruction Microscopy (N-STORM) module, and
400 to 800 consecutive TIRF images were acquired with 10- to 50-ms time
intervals at 100% laser power.
TIRFM Image Analysis and Single-Particle Tracking. Prior to analysis, TIRFM
single images and image series were cropped using ImageJ software. Single-
particle analysis and tracking was performed using u-track software (60) in
MATLAB. Spot intensity data were fetched from the analysis files and plot-
ted in GraphPad Prism and OriginPro. For multi-Gaussian fitting to calculate
different oligomer fractions, the mono-Gaussian distribution properties
(peak value and full-width at half maximum) of a monomeric control and its
increments (2× for dimer, 4× for tetramer) were used as constrained values.
Dimerization kinetics was analyzed implementing the track analysis file
(from u-track analysis) into Polytracker (publicly available at https://github.
com/Blosberg/polytracker) in MATLAB. Collected interaction times were
plotted in GraphPad Prism. A two exponential decay function with a fixed
τ-value (112 ms) for the fast component was employed to obtain the τ-value
and its 95% CIs.
SpIDA. For SpIDA analysis, 3 × 105 HEK293AD cells seeded on clean glass
coverslips in six-well plates were transfected with 500 ng of vector plasmid
for 16 h to 24 h using Effectene transfection reagent (Qiagen) according to
the manufacturer’s protocol. For SNAP-tag incorporated receptors, labeling
was performed as in TIRFM experiments using SNAP-Surface Alexa Fluor 488
dye. Coverslips with transfected cells were placed in an Attofluor cell
chamber (Thermo Fisher Scientific) and supplemented with imaging buffer
(HBSS) supplemented with 0.1% (wt/vol) bovine serum albumin (BSA)
(Sigma-Aldrich). SpIDA imaging was performed using a commercial laser-
scanning confocal microscope (Leica SP8) equipped with a 40×/1.25 NA oil
immersion objective, a white light laser (WLL), and photon counting hybrid
detectors; 488- and 514-nm lines of the WLL were used for excitation, and
emission bands of 500 nm to 650 nm and 520 nm to 600 nm were used for
detection of SNAP-Surface Alexa 488 and EYFP, respectively. Images were
acquired with 10% laser power with a pixel dwell time of 4.88 μs. Image
format was xy, and image size was set to 512 × 512 pixels with 50-nm pixel
size. For ligand treatments, cells were supplemented in imaging chamber
with imaging buffer + corresponding ligand, and then incubated for 20 min
prior to imaging. For time course SpIDA imaging, as soon as ligand was
added, different cells were imaged with 30-s intervals. Image analysis was
performed using the one-population mode of the SpIDA function using a
custom-written MATLAB routine, as described previously (34). Calculated
quantal brightness values are real photon counts per fluorescent molecule
per pixel dwell time. Polygonal region of interest (ROI) selection was
implemented to the MATLAB routine to avoid areas with inhomogeneous
fluorescence distribution (i.e., membrane ruffles, clusters).
TB Analysis. For TB analysis, the same imaging setup was used as for SpIDA
measurements. The imagingmodewas xyt, and 100 frames were takenwith a
pixel dwell time of 2.43 μs, pixel size of 50 nm, and image resolution 256 ×
256 pixels. EYFP-tagged constructs were imaged using a 514-nm line of the
WLL with a laser power of 0.75%, and the Hybrid detector was set between
520 nm and 600 nm. Data were analyzed using a custom-written Igor Pro
routine as described previously (61), incorporating a boxcar average filtering
(62). The brightness values were calculated based on the average of the
brightness values from each pixel within the ROI.
FRET AB Imaging. HEK293AD cells were seeded on glass coverslips and
transfected identically to the SpIDA experiments. Cell were transfected with
CXCR4-EYFP and 250 ng of CXCR4-ECFP together in each well. FRET AB im-
aging was performed using a commercial Leica TCS SP8 confocal laser-
scanning microscope, using the FRET AB module. Image size was 512 ×
512 pixels with 50-nm pixel size and 4.88-μs pixel dwell time. Donor and
acceptor were imaged at the bottom cell membrane (to visualize and avoid
potential heterogeneities on the membrane) using a 405-nm laser at 1%
laser power for ECFP excitation, and emission was detected within a wave-
length window of 450 nm to 490 nm. For EYFP excitation, the 514-nm laser
line of the WLL was used at 1%, and emission was detected between 520 nm
and 600 nm. Photomultiplier tube (PMT)-based detectors (with 700-V gain)
were used for emission reading. EYFP photobleaching was performed by
acquiring 10 images with the 514-nm laser line at 50% laser power. Inho-
mogeneous areas of the cells were carefully excluded during ROI selection.
CXCR4 Immunostaining. HEK293AD and CHO cells were seeded on glass
coverslips in six-well plates and transfected with CXCR4-ECFP or β1AR-ECFP;
24 h after transfection, cells were washed three times with PBS, and then
PBS was replaced with 1% BSA in FluoroBrite medium (Gibco). After 1 h
incubation at 37 °C and 5% CO2, cells were washed three times with PBS and
were further incubated at 37 °C and 5% CO2 with 20 μg/mL human CXCR4
Alexa Fluor 488-conjugated antibody (FAB173G, R&D Systems) in FluoroBrite
medium supplemented with 1% BSA; 1 h after incubation, cells were washed
three times with PBS and incubated in FluoroBrite medium supplemented
with 1% BSA for 3 × 10 min. After the last incubation, cells were imaged
with a Leica TCS SP8 confocal laser-scanning microscope. CFP was excited
using a 405-nm diode laser at 10% power and detected within the emission
window of 430 nm to 490 nm. Alexa Fluor 488 was excited using the 492-nm
laser line of the WLL at 10% power, and detected within the emission
window of 500 nm to 650 nm. Image size was 512 × 512 pixels with 50-nm
pixel size and 4.88-μs pixel dwell time.
BRET-Based Receptor−Gγ Interaction Assay. HEK293AD cells were seeded in
10-cm cell culture dishes at a density of 2 × 106 cells and transfected 24 h after
seeding with 500 ng of CXCR4-nanoLuc, 800 ng of Gαi2, 500 ng of Gβ1, and
200 ng of Gγ2-SYFP constructs using Effectene transfection reagent (Qiagen)
according to the manufacturer’s protocol; 24 h after transfection, cells were
transferred into a white-walled, white-bottom 96-well plate, at a density of
105 cells per well; 16 h to 24 h after reseeding, medium was removed, cells
were washed with PBS and then supplemented with 90 μL HBSS containing
furimazine (Promega) (1:1,000 vol/vol). After 10-min incubation at 37 °C,
measurement was performed at 37 °C using a Synergy Neo2 Plate Reader
(Biotek) using BRET2 filter set. Delta (Δ) BRET for each well was calculated
according to the formula
%ΔBRET = (BRETpost − BRETpre
BRETpre
) × 100,
where BRETpost is the average BRET ratio values of poststimulus, and BRETpre
is the average BRET ratio values measured prestimulus. In each 96-well plate,
maximum % ΔBRET observed for CXCL12 stimulus is defined as −100%, and
every other % ΔBRET value is then normalized to this.
BRET-Based Receptor−β-Arrestin Interaction and Internalization Assays.
HEK293AD cells were seeded in 10-cm cell culture dishes at a density of
2 × 106. For arrestin recruitment assay, cells were cotransfected with 1000 ng
of CXCR4-nLuc and 1,000 ng of human β-arrestin2-HaloTag. For internali-
zation assay, a plasmid construct bearing two HaloTags, separated by a re-
petitive rigid linker, and an N-terminal Lyn-derived sequence (GCIKSKRKDK)


























and a C-terminal farnesylation sequence (KKKSKTKCVIM) for plasma mem-
brane localization was used. Then 1,500 ng of this plasmid was cotransfected
with 500 ng of CXCR4-nLuc 24 h after seeding, and the cells were transferred
into a while-walled, white-bottom 96-well plate, at a density of 105 cells per
well, and cells were labeled for at least 16 h with HaloTag 618 Ligand
(Promega); 16 h to 24 h after reseeding, medium was removed, and cells
were washed with PBS and then supplemented with 90 μL HBSS containing
furimazine (Promega) (1:1,000 vol/vol). After 10 min incubation at 37 °C,
measurement was performed at 37 °C using a Synergy Neo2 Plate Reader
(Biotek) using the NanoBRET filter set.
FRET-Based Gi2 Protein Activation Assay.HEK293AD cells were seeded in 10-cm
cell culture dishes at a density of 2 × 106. Cells were cotransfected with 500 ng
of CXCR4 and 1,500 ng of Gi2 FRET sensor 24 h after seeding, as described in
previous sections; 24 h after transfection, cells were trypsinized and trans-
ferred into a black-walled, black-bottom 96-well plate, at a density of 105
cells per well; 16 h to 24 h later, cells were washed with prewarmed PBS, and
then 90 μL of prewarmed HBSS was added to each well. After 10-min in-
cubation at 37 °C, measurement was performed at 37 °C using a Synergy
Neo2 Plate Reader (Biotek) using a CFP/YFP FRET filter set. After basal FRET
measurement, 10 μL of decreasing concentrations of ligands were added to
the wells, and FRET ratio was measured again. Delta FRET for each well was
calculated according to the formula
%ΔFRET = (FRETpost − FRETpre
FRETpre
) × 100,
where FRETpost is the average FRET ratio values of poststimulus, and FRETpre
is the average FRET ratio values measured prestimulus.
CXCR4 Ligand Docking. CXCR4 ligand binding modes were obtained with
different methods. VUN401 was docked in the CXCR4 crystal structure with
Protein Data Bank (PDB) ID code 3ODU (21) using High Ambiguity Driven
Biomolecular Docking (HADDOCK) (63) and incorporating the experimen-
tally validated interacting residue Arg30 (40) as active residue for guiding
the docking. The T140-derivative peptide TC14012 was modeled based on
the CVX15 crystallized structure (PDB ID code 3OE0) (21) from which the last
two residues were deleted. AMD3100, AMD3465, and FC131 were docked
using the induced-fit docking program of Schrödinger. Residues known from
literature to be key for the binding of these ligands were used as restraints:
for FC131, residues Asp97, Asp171, and Tyr255 were used (47, 64); for
AMD3100 and AMD3465, residues Asp171, Asp262, and Glu288 were used
(45, 65–67). IT1t binding mode was directly extracted from the crystal
structure (PDB ID code 3ODU) (21). The CXCL12:CXCR4 complex was
extracted from a recently published model (68).
Quantification and Statistical Analysis. In scatter dot plots, where average
oligomeric sizes are compared, an ordinary one-way ANOVA test in Graph-
pad Prism was used with Tukey’s multiple comparison test, including no
matching or pairing. For Figs. 3A and 4A and SI Appendix, Fig. S6B, a com-
plete table of statistical significance analysis is provided in SI Appendix. In
text, statistical significance is referred to a P value < 0.001 from Tukey’s
multiple comparison test. Statistical analysis of the basal Gi2 sensor FRET
ratios (Fig. 6C and SI Appendix, Fig. S6A) was performed using a paired t test
using GraphPad Prism. Outlier analysis on the Fig. 4C was done by using
robust regression followed by outlier identification (ROUT) method choos-
ing the false discovery rate (Q) as 1.
Data Availability. All study data are included in the article and SI Appendix.
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